Scott A. Long
Pfizer (United States)(US)Charles River Associates(US)
Publications by Year
Research Areas
Surfactants and Colloidal Systems, Synthesis and biological activity, Cell death mechanisms and regulation, Cannabis and Cannabinoid Research, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7 Inhibit Apoptosis and Maintain Cell Functionality(2000)232 cited
- → Potent and Selective Nonpeptide Inhibitors of Caspases 3 and 7(2001)164 cited
- → Discovery of (3S,3aR)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy(2010)91 cited
- → Chiral Organolithium Complexes: The Structure of β-Lithiated β-Phenylcarboxamides and the Mechanism of Asymmetric Substitution in the Presence of (−)-Sparteine(1996)51 cited
- → Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency(2009)46 cited
- → Benzothiophene inhibitors of MK2. Part 1: Structure–activity relationships, assessments of selectivity and cellular potency(2009)42 cited
- → Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode(2010)35 cited
- → Discovery of 3-Cyano- N -(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H -pyrrolo[2,3- b ]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist(2018)32 cited
- → Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain(2011)31 cited
- → Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa(2007)22 cited